Pulmonx
- Beran Rose
Beran has 20 years of experience driving growth through product strategy, market development, and commercial execution. Prior to Pulmonx, Beran was Global Group Marketing Director at Boston Scientific, where he was responsible for building BSC’s Pulmonary business. He built a new product portfolio and created the market for the first procedure to treat severe asthma. Prior to his role in marketing, Beran was a director of strategy within the R&D and clinical organizations of Boston Scientific. Prior to Boston Scientific, Beran has a decade of management consulting experience for leading healthcare and high-tech companies in Europe and the USA. Beran received a BA from Yale University and an MBA from the MIT Sloan School of Management.
Org chart
Upgrade to view 21 reports
Offices
This person is not in any offices
Pulmonx
1 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1
